Buccoadhesive films for once-a-day administration of rivastigmine: Systematic formulation development and pharmacokinetic evaluation

Drug Development and Industrial Pharmacy

Volumn 39, Issue 3, 2013, Pages 466-480

  Kapil, Rishi ^a   Dhawan, Sanju ^a   Beg, Sarwar ^a   Singh, Bhupinder ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Alzheimer's disease; FbD; IVIVC; Mucoadhesion; Sustained release; Transmucosal

Indexed keywords

POLYMER; RIVAMER; RIVASTIGMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BUCCOADHESIVE FILM; CONTROLLED DRUG RELEASE; DRUG DESIGN; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; FILM; MALE; NONHUMAN; RABBIT;

ADHESIVENESS; ADMINISTRATION, BUCCAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG DELIVERY SYSTEMS; MOUTH MUCOSA; PHENYLCARBAMATES; RABBITS;

EID: 84864604565     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.665926     Document Type: Article

References (43)

1. Mutlu NB, Degim Z, Yilmaz S, Essiz D, Nacar A. (2011). New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations. Drug Dev Ind Pharm, 37:775-789.
2. Drach LM. Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia-common features and differences. Med Monatsschr Pjarm. 2011;34:47-52.
3. Kapil R, Beg S, Singh B. (2012) Alzheimer's disease: pathology and treatment strategies. Trendz in Med World. 6: 31-41.
4. Inglis F. (2002). The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl: 45-63.
5. Jhee SS, Shiovitz T, Hartman RD, Messina J, Anand R, Sramek J et al. (2002). Centrally acting antiemetics mitigate nausea and vomiting in patients with Alzheimer's disease who receive rivastigmine. Clin Neuropharmacol, 25:122-123.
6. Darvesh S, Walsh R, Kumar R, Caines A, Roberts S, Magee D et al. (2003). Inhibition of human cholinesterases by drugs used to treat Alzheimer disease. Alzheimer Dis Assoc Disord, 17:117-126.
7. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr Ther Res. 2003;64:216-235.
8. Jann MW, Shirley KL, Small GW. (2002). Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet, 41:719-739.
9. Wentrup A, Oertel WH, Dodel R. (2009). Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther, 2:245-254.
10. Llabot JM, Palma SD, Manzo RH, Allemandi DA. (2007). Design of novel antifungal mucoadhesive films. Part II. Formulation and in vitro biopharmaceutical evaluation. Int J Pharm, 336: 263-268.
11. Peh KK, Wong CF. Polymeric films as vehicle for buccal delivery: swelling, mechanical, and bioadhesive properties. J Pharm Pharm Sci. 1999;2:53-61.
12. Singh S, Soni R, Rawat MK, Jain A, Deshpande SB, Deshpande SB et al. (2010). In vitro and in vivo evaluation of buccal bioadhesive films containing salbutamol sulphate. Chem Pharm Bull, 58:307-311.
13. Kapil R, Dhawan S, Singh B. (2009). Development and validation of a spectrofluorimetric method for the estimation of rivastigmine in formulations. Indian J Pharm Sci, 71:585-589.
14. Liltorp K, Larsen TG, Willumsen B, Holm R. (2011). Solid state compatibility studies with tablet excipients using non thermal methods. J Pharm Biomed Anal, 55:424-428.
15. Monajjemzadeh F, Hassanzadeh D, Valizadeh H, Siahi-Shadbad MR, Mojarrad JS, Robertson TA et al. (2009). Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets. Eur J Pharm Biopharm, 73:404-413.
16. Singh B, Kumar R, Ahuja N. (2005). Optimizing drug delivery systems using systematic "design of experiments." Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst, 22:27-105.
17. Dhawan S, Kapil R, Singh B. (2011). Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol, 63:342-351.
18. Singh B, Singh S. A compreshensive computer program for study of drug release kinetics from compressed matrices. Indian J Pharm Sci. 1998;60:313-316.
19. Singh B, Kaur T, Singh S. Correction of raw dissolution data for loss of drug during sampling. Indian J Pharm Sci. 1997;59:196-199.
20. Singh B, Ahuja N. (2002). Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: optimization of bioadhesion, dissolution, and diffusion parameters. Drug Dev Ind Pharm, 28:431-442.
21. Zhang H, Robinson JR. In Vitro Methods for Measuring Permeability of the Oral Mucosa. In: Rathbone MJ, editor. Oral Mucosal Drug Delivery; Drugs and The Pharmaceutical Sciences. New York: Marcel Dekker; 1996. p. 85-100.
22. Rajput G, Majmudar F, Patel J. (2011). Formulation and evaluation of mucoadhesive glipizide films. Acta Pharm, 61:203-216.
23. ICH. The European agency for the evaluation of medical products. Topic Q2B: Note for guidance on validation of analytical procedures: Methodology. GPMP/ICH. 1996281/95.
24. USP. USP 27, NF 22 The United States Pharmacopeia and The National Formulary, Rockwille, MD: The United States Pharmacopeial Convention; 20852 ISSN: 0195-7996, ISBN: 1-889788-20-0. 2004
25. Reagan-Shaw S, Nihal M, Ahmad N. (2008). Dose translation from animal to human studies revisited. FASEB J, 22:659-661.
26. Rossi RC, Dias CL, Bajerski L, Bergold AM, Fröehlich PE. (2011). Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data. J Pharm Biomed Anal, 54:439-444.
27. Singh B, Kapil R, Nandi M, Ahuja N. (2011). Developing oral drug delivery systems using formulation by design: vital precepts, retrospect and prospects. Expert Opin Drug Deliv, 8:1341-1360.
28. Singh B, Chakkal SK, Ahuja N. (2006). Formulation and optimization of controlled release mucoadhesive tablets of atenolol using response surface methodology. AAPS PharmSciTech, 7:E3.
29. Li L, Zhao X, Yang C, Hu H, Qiao M, Chen D. (2011). Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology. Drug Dev Ind Pharm, 37:1170-1180.
30. Siddique S, Bose A, Khanam J. (2011). Modulation of drug (metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix. Drug Dev Ind Pharm, 37:1016-1025.
31. Shayeda, Gannu R, Palem CR, Rao YM. Development of novel bioadhesive buccal formulation of diltiazem: in vitro and in vivo characterization. PDA J Pharm Sci Technol. 2009;63:401-408.
32. Hassan N, Khar RK, Ali M, Ali J. (2009). Development and evaluation of buccal bioadhesive tablet of an anti-emetic agent ondansetron. AAPS PharmSciTech, 10:1085-1092.
33. Tamilvanan S, Bangale GS, Ananthi JJ, Sivakumar V, Vinothapooshan G, Palanivelu M et al. (2009). Carvedilol-loaded mucoadhesive buccal tablets: influence of various mucoadhesive polymers on drug release behavior. PDA J Pharm Sci Technol, 63:196-206.
34. Yehia SA, El-Gazayerly ON, Basalious EB. (2009). Fluconazole mucoadhesive buccal films: in vitro/in vivo performance. Curr Drug Deliv, 6:17-27.
35. Singh B, Pahuja S, Kapil R, Ahuja N. (2009). Formulation development of oral controlled release tablets of hydralazine: optimization of drug release and bioadhesive characteristics. Acta Pharm, 59:1-13.
36. Singh B, Rani A, Babita, Ahuja N, Kapil R. (2010). Formulation Optimization of Hydrodynamically Balanced Oral Controlled Release Bioadhesive Tablets of Tramadol Hydrochloride. Sci Pharm, 78:303-323.
37. Mughal MA, Iqbal Z, Neau SH. (2011). Guar gum, xanthan gum, and HPMC can define release mechanisms and sustain release of propranolol hydrochloride. AAPS PharmSciTech, 12:77-87.
38. Aguilar-de-Leyva A, Sharkawi T, Bataille B, Baylac G, Caraballo I. Release behaviour of clozapine matrix pellets based on percolation theory. Int J Pharm. 2011;404:133-141.
39. Pan J, Lu W, Li C, Wang S, He L. (2010). Imperatorin sustainedrelease tablets: In vitro and pharmacokinetic studies. Arch Pharm Res, 33:1209-1216.
40. Patel VM, Prajapati BG, Patel HV, Patel KM. (2007). Mucoadhesive bilayer tablets of propranolol hydrochloride. AAPS PharmSciTech, 8:E77.
41. Venugopal K, Movva S, Saha RN. New, rapid, and sensitive spectrofluorimetric method for the estimation of gatifloxacin in bulk and formulations. Indian J Pharm Sci. 2006;68:726.
42. Cummings J, Lefèvre G, Small G, Appel-Dingemanse S. (2007). Pharmacokinetic rationale for the rivastigmine patch. Neurology, 69:S10-S13.
43. Sankalia JM, Sankalia MG, Mashru RC. (2008). Drug release and swelling kinetics of directly compressed glipizide sustainedrelease matrices: establishment of level A IVIVC. J Control Release, 129:49-58.